NasdaqGS:GRALBiotechs
A Look At GRAIL (GRAL) Valuation As FDA PMA Submission For Galleri Test Reaches Final Stage
GRAIL (GRAL) is in focus after submitting the final module of its Premarket Approval application to the US Food and Drug Administration for the Galleri multi cancer early detection blood test.
See our latest analysis for GRAIL.
The PMA submission arrives after a sharp 6.2% 1 day share price decline to US$98.88. However, the 90 day share price return of 23.51% and 1 year total shareholder return of 187.53% still point to strong recent momentum around the company.
If this kind of regulatory...